Post-earnings recap
Reported
Mon, Aug 8, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a wider-than-expected loss per share, which contributed to a 7.81% drop in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. Management's cautious tone suggests they are aware of the challenges ahead and are focusing on long-term strategies.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | -14.58% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced during the quarter. They emphasized the importance of strategic planning moving forward.
Management expressed concerns about ongoing challenges in the market.
They highlighted the need for continued focus on product development.